Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 160

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 160
---
 Total stockholders’ equity

    81,849

    124,701

    Total liabilities and stockholders’ equity
     
    $
    92,087

    $
    138,744

The accompanying notes are an integral part of these financial statements.

F-3

AN2 THERAPEUTICS, INC.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

 (in thousands, except share and per share amounts)

    Year Ended December 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    40,488

    $
    54,871

    General and administrative

    14,066

    14,764

    Restructuring charges

    2,234

    —

    Total operating expenses

    56,788

    69,635

    Loss from operations

    (56,788
    )

    (69,635
    )

    Interest income

    5,467

    4,860

    Other income

    —

    43

    Net loss

    (51,321
    )

    (64,732
    )

    Net loss per share attributable to common stockholders, basic and diluted
     
    $
    (1.72
    )
     
    $
    (2.74
    )

    Weighted-average number of shares used in computing net loss per share,basic and diluted

    29,828,227

    23,600,107

    Other comprehensive loss:

    Unrealized (loss) gain on investments

    (244
    )

    649

    Comprehensive loss
     
    $
    (51,565
    )
     
    $
    (64,083
    )

The accompanying notes are an integral part of these financial statements.

F-4

AN2 THERAPEUTICS, INC.

STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share and per share amounts)

    Common Stock

    AdditionalPaid-In

    Accumulated Other Comprehensive

    Accumulated

    TotalStockholders’

    Shares

    Amount

    Capital

    Gain (Loss)

    Deficit

    Equity

    Balances at December 31, 2022

    19,402,658

    $
    —

    $
    185,469

    $
    (374